Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Spinraza
Spinraza
Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win
Fierce Pharma
Wed, 09/4/24 - 10:49 pm
Biogen
Spinraza
SMA
spinal muscular atrophy
Spinal Muscular Atrophy: Four trials to watch over the next 12 months
Clinical Trials Arena
Fri, 08/11/23 - 11:39 am
clinical trials
spinal muscular atrophy
Scholar Rock
apitegromab
Novartis
Zolgensma
Spinraza
clenbuterol
Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza
Fierce Pharma
Tue, 01/10/23 - 10:55 am
Biogen
Alcyone Therapeutics
SMA
Spinraza
devices
Medtech
Biogen Announces New Spinraza Data Ahead of Presentation
BioSpace
Mon, 03/14/22 - 11:39 pm
Biogen
Spinraza
SMA
spinal muscular atrophy
Biogen brings in a successor to Spinraza
BioPharma Dive
Tue, 01/4/22 - 10:49 pm
Biogen
Ionis Pharmaceuticals
Spinraza
BIIB115
antisense
spinal muscular atrophy
Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial
Fierce Pharma
Thu, 09/16/21 - 10:52 am
Biogen
Spinraza
SMA
Roche
Evrysdi
spinal muscular atrophy
Zolgensma flatlines, but Spinraza isn’t the beneficiary
EP Vantage
Wed, 04/28/21 - 10:27 am
SMA
Biogen
Novartis
Roche
Spinraza
Zolgensma
Evrysdi
Biogen Reports New Spinraza Data in SMA
Global Genes
Wed, 04/21/21 - 10:34 am
Biogen
Spinraza
SMA
2 Fumbles and 1 Gift in Biogen's Latest Earnings Report
Motley Fool
Wed, 10/28/20 - 10:38 am
Biogen
earnings
Spinraza
Biogen is running out of safety nets
BioPharma Dive
Thu, 10/22/20 - 10:53 am
Biogen
Vumerity
Tecfidera
Spinraza
aducanumab
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
BioPharma Dive
Mon, 10/5/20 - 11:39 pm
SMA
spinal muscular atrophy
Novartis
Zolgensma
Spinraza
Roche
Evrysdi
Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”
BioSpace
Wed, 08/12/20 - 12:14 am
Biogen
SMA
spinal muscular atrophy
Spinraza
clinical trials
Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients
MedCity News
Tue, 07/21/20 - 10:37 am
Biogen
clinical trials
Spinraza
Novartis
Zolgensma
SMA
spinal muscular atrophy
Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients
BioSpace
Wed, 06/10/20 - 11:46 pm
Biogen
SMA
Spinraza
clinical trials
Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst
Fierce Pharma
Wed, 04/8/20 - 11:03 am
Roche
FDA
risdiplam
Biogen
Spinraza
Novartis
Zolgensma
SMA
Should Biogen's Spinraza for SMA be delayed amid COVID-19? No, say these parents
Fierce Pharma
Fri, 03/27/20 - 12:02 am
Biogen
SMA
Spinraza
COVID-19
Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis
Endpoints
Mon, 11/25/19 - 09:52 am
Roche
PTC Therapeutics
SMA
risdiplam
Biogen
Spinraza
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Investors Business Daily
Sat, 09/21/19 - 12:28 pm
Wave Life Sciences
suvodirsen
DMD
Merck
Keytruda
Biogen
Spinraza
Zoetis
Europe
animal health
Jazz Pharmaceuticals
JZP-258
narcolepsy
Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
Fierce Pharma
Wed, 09/18/19 - 11:21 am
Biogen
clinical trials
Spinraza
SMA
spinal muscular atrophy
Novartis
Threats to Spinraza are mounting, but Biogen still has cards to play
EP Vantage
Mon, 07/1/19 - 07:25 pm
Biogen
SMA
Spinraza
Novartis
Roche
risdiplam
Zolgensma
Pages
1
2
3
next ›
last »